Gimv NV (GIMB.BR): BCG Matrix [Apr-2026 Updated]

Gimv's portfolio is increasingly tilted toward high-growth winners-Sustainable Cities and Healthcare-which delivered double-digit returns and are absorbing fresh capital and bolt‑on deals, while cash-generating Smart Industries and new Anchor holdings underpin dividends and liquidity; riskier bets in Life Sciences and Consumer demand heavy R&D and scaling to justify further investment, and management is pruning legacy "dogs" to recycle proceeds into the growth engines-keep reading to see how these allocation choices shape Gimv's path to higher value and a larger, more focused portfolio.

Gimv NV (GIMB.BR) - BCG Matrix Analysis: Stars

Stars

The Stars category for Gimv is dominated by two high-growth, high-share platforms: Sustainable Cities and Healthcare. Both platforms exhibit double-digit EBITDA expansion, strong unrealized results and materially outperform the broader portfolio in total portfolio return during H1 2025, reflecting market leadership and significant reinvestment potential.

Sustainable Cities platform delivered exceptional performance in H1 2025 with a 24.0% total portfolio return versus the overall portfolio return of 9.5%. Organic revenue and EBITDA expansion, combined with targeted buy-and-build acquisitions, produced an unrealized result of EUR 28.3 million. The platform accounted for 29% of Gimv's new investments by value as of early 2025 and targets construction, energy and logistics sub-sectors where market growth and CAPEX intensity are high.

Sustainable Cities growth drivers and strategic actions:

• Organic EBITDA expansion through operational improvements and platform synergies.
• Buy-and-build acquisitions to accelerate scale and extend geographic footprint.
• High CAPEX allocation to portfolio leaders (e.g., Hemink, Acceo) to secure market leadership and technology adoption.
• Exposure to secular trends: urbanization, energy transition and resilient logistics demand.

Healthcare platform realized double-digit EBITDA growth in H1 2025 and produced an 11.6% total portfolio return. The platform accounted for 30% of Gimv's total investments in FY 2024-2025 and delivered an unrealized result of EUR 29.7 million across 64 portfolio companies. Investments in Ambulantis and Novicare underscore Gimv's focus on high-growth subsectors within the DACH and Benelux regions, leveraging specialized sector expertise to capture market share and expand margins.

Healthcare platform growth drivers and strategic actions:

• Resilient organic revenue growth driven by demographic trends and increasing care demand.
• Margin expansion via operational improvements, scale effects and specialized management support.
• Geographic focus on DACH and Benelux to exploit regulatory familiarity and payer landscapes.
• Active portfolio management to prepare high-value exit opportunities given strong sector M&A interest.

Comparative snapshot of Star platforms (H1 2025):

Gimv NV (GIMB.BR) - BCG Matrix Analysis: Cash Cows

Cash Cows

The Smart Industries platform functions as Gimv's primary cash cow, generating effective cash flow despite a broader industrial slowdown in Europe. In H1 2025 the platform delivered a portfolio return of 8.7% while the broader industrial sector showed muted growth, supporting steady distributions to the parent company. By September 2025 the Smart Industries and related mature holdings accounted for a material portion of total portfolio value, contributing to an aggregate portfolio valuation peak of 2,000 million EUR.

The Anchor investment strategy complements Smart Industries by providing long-term stability and recurring income. Anchor targets larger, mature holdings (example: Cegeka with 1,300 million EUR in revenue) and focuses on larger stakes to secure dividend flows and lower volatility. Anchor contributed materially to the record net profit of 219 million EUR for the 2024-2025 fiscal year and delivered a net return on equity of 14.7% for the period.

Key financial metrics and portfolio characteristics for Gimv's Cash Cows are summarized below.

Operational and financial characteristics that define these Cash Cows:

• Mature companies with strong market positions and predictable cash conversion.
• Stable weighted average EBITDA multiple (~9.7-10.2x) reflecting quality assets.
• Deleveraging trend across holdings, improving free cash flow generation.
• Significant contribution to dividends and group liquidity management (2.6 EUR/share payout in 2025).
• Anchor stakes provide lower volatility income and capital appreciation potential (net ROE 14.7%).

Cash flow dynamics and uses:

• Operating cash inflows from Smart Industries used to finance distributions, follow-on investments, and operational expenses.
• Anchor dividends and realizations channeled into capital calls for growth platforms and to maintain dividend policy.
• Cash coverage metrics: estimated free cash flow cover for dividends ~1.1x in 2025 based on platform cash generation vs. 2.6 EUR/share payout.

Risks and sensitivities specific to the Cash Cows:

• Sensitivity to European industrial cycle-prolonged economic cooling could compress returns below 8%-9% band.
• Valuation risk if EBITDA multiples contract materially from ~9.7x, reducing mark-to-market portfolio value.
• Concentration risk from large Anchor stakes-while lowering volatility, these can tie up liquidity if exit markets deteriorate.

Gimv NV (GIMB.BR) - BCG Matrix Analysis: Question Marks

Question Marks - Life Sciences platform

The Life Sciences platform represents high-growth potential but currently exhibits valuation volatility and negative near-term portfolio returns. In H1 2025 the platform reported a portfolio return of -5.6% driven by standalone partial write-downs on select R&D-driven companies. Despite this, Gimv continued heavy capital deployment: Kivu Bioscience closed a Series A of USD 92 million during the period, and total platform investment represented 9% of Gimv's investment mix for the 2024-2025 fiscal year.

The market backdrop shows rapid growth in biotech and medical innovation, with global biopharma R&D spend increasing by mid-teens CAGR in recent years and addressable market expansion in cell & gene therapies and specialty biologics. However, most Life Sciences holdings are pre-revenue and require sizeable CAPEX and extended timelines for clinical development. Success hinges on clinical milestone delivery, regulatory progress, and the ability to achieve value-inflection events that permit either strategic exits or transitions into the Stars quadrant.

• Key upside drivers: successful Phase II-III readouts, regulatory approvals, strategic M&A at high multiples.
• Key risks: binary clinical outcomes, valuation write-downs, long cash burn and dilution, specialized management needs.
• Gimv action points: continued selective follow-on funding, board and governance support, de-risking through milestone-based financing.

Question Marks - Consumer platform

The Consumer platform navigates a sluggish consumer-spending environment, targeting niche market leaders and resilient subsectors. In H1 2025 the platform produced a modest portfolio return of 2.5% as inflation and macro uncertainty dampened discretionary demand. Prior periods recorded 30% EBITDA growth in aggregated portfolio companies, but momentum slowed in 2024-2025. Gimv allocated EUR 66.8 million to the Consumer segment in the 2024-2025 fiscal year, prioritizing companies with differentiating strategies and strong unit economics.

Recent strategic moves include acquisitions such as Alpine and The Spice Factory aimed at consolidating niche positions and capturing resilient margin pools. The platform's ability to convert Question Marks into Stars depends on consumer confidence recovery, successful scaling of recent acquisitions, and margin expansion through pricing power, supply-chain optimization and premiumization.

• Key upside drivers: recovery in consumer confidence, successful integration and scaling of acquisitions, execution on digital and margin initiatives.
• Key risks: prolonged inflation, cost pressures, loss of discretionary spend, competitive pricing actions.
• Gimv action points: selective follow-on investment, operational support for roll-ups, focus on resilient subsegments and margin improvement.

Gimv NV (GIMB.BR) - BCG Matrix Analysis: Dogs

Non-core legacy holdings classified as 'Dogs' have been the primary focus of Gimv's portfolio optimization through active divestment during FY 2024-2025. Five participations-including United Dutch Breweries and Medi-Markt-were sold, generating exit proceeds of 560 million EUR versus 364.6 million EUR in the prior year. The rotation increased Gimv's cash position to 668.8 million EUR as of March 2025 and supported a net asset value (NAV) of 53.9 EUR per share reported in September 2025. These disposals enable redeployment of capital into higher-growth platforms such as Sustainable Cities and Healthcare.

Certain Smart Industries holdings, heavily exposed to the weak European manufacturing cycle, have been identified as Dogs due to low growth and low ROI. Exceptional write-downs on these positions have materially reduced near-term segment performance and contributed to a drag on group-level metrics. Management has initiated active monitoring and potential restructuring or sale processes to remove these assets from the core portfolio and protect overall returns.

Key characteristics and consequences of Dogs within Gimv's portfolio:

• Low organic revenue growth and limited TAM expansion in legacy industrial subsegments.
• Disproportionate capital consumption and underperformance leading to write-downs.
• Negative contribution to aggregated portfolio return (drag on 9.5% overall).
• Pressure on group ROE, necessitating exit or restructuring to restore 14.7% target levels.
• Reallocation of proceeds to high-growth platforms to support the double-by-2030 ambition.

Management actions and financial impacts associated with disposing Dogs:

• Accelerated divestment process for five non-core participations in FY 2024-2025, realizing 560.0 million EUR in proceeds.
• Improved liquidity buffer: cash increased to 668.8 million EUR (Mar 2025), enabling selective follow-on investments in Sustainable Cities and Healthcare.
• Active monitoring of Smart Industries exposures with plans for restructuring, sale, or carve-outs to protect average EBITDA multiple (9.7x) and restore portfolio return trajectory.
• Allocation of exit proceeds contributed to NAV uplift to 53.9 EUR per share (Sep 2025), improving shareholder value metrics.

Operational and market risks tied to Dogs that require continuous oversight:

• Regional economic slowdown in European manufacturing prolonging recovery and depressing exit valuations.
• Sustained low margins in certain industrial niches that reduce potential M&A interest and extend hold periods.
• Potential timing mismatch between market windows for exits and Gimv's need to redeploy capital into higher-growth verticals.
• Execution risk on restructurings could incur additional write-downs and temporarily reduce ROE below target levels.